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-INTRODUCTION 
Cystic fibros~s is a genetically determined disease inherited as a 
Mendelian autosomal recessive trait. The nature and identity of this gene or 
possibly gene cluster is as yet unknown. Unlike such genetic conditions as 
Tay-Sachs disease, sickle cell anemia, or Lesch-Nyhan syndrome, which all have 
characterizable primary biochemical abnormalities, there is no such marker in 
cystic fibrosis. It has been suggested by Conneally et al. (10) that the in-
cidence of expressed cystic fibrosis ranges between 1 in 1900 to 1 in 4000 
live births from caucasian populations in several countries worldwide. Accord-
ing to Di Sant'Agnese (13) the overall incidence of homozygotes for cystic 
fibrosis in the total population of the United States is near 1 in 2000, with 
a heterozygote incidence of 5 percent in the overall population, making cystic 
fibrosis the most common fatal genetic disease among whites in this country. 
Di Sant'Agnese (13) has written an enlightening review of the symptomatology 
of the disease. Briefly, the disease produces a cluster of symptoms including 
failure to thrive, steatorrhea due to pancreatic achylia, increased sweat 
electrolytes, and abnormal mucus secretions in the lungs, upper respiratory 
tract, and nasopharynx resulting in nasal polyps and recurrent, eventually 
terminal pneumonias. In approximately 15% of newbo!'}l infants with cystic 
fibrosis, meconium ileus with or without other obstructive intestinal com-
plications are found and require innnediate surgical obviation. Currently, 
diagnosis of the disease is made on the basis of significantly increased sweat 
electrolytes in cystic fibrosis patients. This test is usually performed after 
other symptoms such as failure to thrive, chronic or recurrent pulmonary 
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difficulties, and steatorrhea have been observed in varying degrees. Fre-
quently these three.most outstanding symptoms occur conconunitantly. Rennert 
(44) has proposed some additional laboratory tests which yet require further 
investigation before being employed clinically. There are two tests mentioned 
in particular which seem to give most promise. These tests are theoretically 
able to ascertain the presence of heterozygote as well as homozygote conditions 
making them of potential use in genetic counselling. One test is based on the 
presence of ciliary dyskinetic factor present in the serum of both homozygotes 
and heterozygotes. The other test of potential usefulness is that which employs 
skin fibroblast tissue cultures and temporary lymphocyte cultures of homo-
zygotes and heterozygotes of the cystic fibrosis gene. These cells show 
significantly under-methylated RNA when compared to control subjects. 
Current treatment for patients with cystic fibrosis has been essentially 
supportive. The review of Di Sant'Agnese (13) described some of the palliative 
procedures employed in the treatment of cystic fibrosis. Doyle (18) gives a 
further description of current techniques of postural drainage and breathing 
exercises for patients with cystic fibrosis. Procedures employed include 
assuaging pulmonary problems by means of prophylactic and therapeutic anti-
biotic therapy for controlling bacterial infections, and postural drainage to 
facilitate removal of thick and copious mucus secretions as well as nebulizer 
and mist tent therapy. Dietary management consists of high carbohydrate and 
protein diets with moderate fat intake. This is supplemented with porcine or 
other pancreatic enzyme preparations to aid digestion. Salt replacement therapy 
may be instituted either prophylactically, especially during hot sunnner weather, 
or therapeutically in the case of heat prostration. Surgical intervention is 
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not commonly employed, although it is necessary in such cases as meconium ileus 
or other intestinal-Obstructive complications. A further account of surgical 
treatment of pulmonary complications has been given by Holsclaw and Shwachman 
(31). They suggest surgical intervention, tube thoracostomy in the cases of 
severe degrees of pneumothorax or thoractomy with lung resection in the cases 
of bronchiectasis or frank lung abscess. 
Research has been launched on several fronts of the problem concerning 
cystic fibrosis. This work can be broadly categorized under two basic headings: 
first, that which is involved with the cause of the disease including the 
identification of the essential genetic lesion(s) and its (their) immediate 
and primary biochemical and biophysical consequences, and second, that con-
cerned with the secondary clinical manifestations, particularly in the area of 
bacterial respiratory infections and the relationship between cystic fibrosis 
patients and their peculiar bacterial flora. 
Much research has been done in elucidating the basic and primary nature 
of this disease. Mccombs (37) has written a substantial review of investiga-
tions conducted in this area of cystic fibrosis research both original and 
current. Major efforts here seem to be in four broad directions, the study of 
skin fibroblast and leukocyte tissue cultures from cystic fibrosis patients 
and carriers and their production of atypical biochemical substances, the study 
of the serum protein ciliary dyskinetic factor in both homozygotes and hetero-
zygotes, the study of membrane transport abnormalities in cystic fibrosis 
patients, and the study of the composition and nature of mucus sols, saliva, 
and sweat as well as the physiology of their secretion. 
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Since the nature of this particular investigation is essentially 
concerned with the secondary clinical manifestations of this disease, 
namely, pulmonary infections with Pseudomonas aeruginosa, a more detailed 
,literature review shall follow including the statement of purpose. 
PURPOSE AND LITERATURE SURVEY 
The purpose of this thesis is basically threefold. First, this project 
aims to determine the incidence, prevalence, and maintenance of Pseudomonas 
aeruginosa respiratory tract infections in cystic fibrosis patients by means 
of pyocine typing. Secondly, by means of nitro blue tetrazolium, stimulated 
and unstimulated tests of cystic fibrosis patients, severely and moderately 
to mildly affected, and adequate control subjects, it will be determined 
whether or not significant differences exist in test results between the 
three parameters mentioned above. Thirdly, an investigation is to be made 
into the possible effect of mucoid slime of certain strains of P. aeruginosa 
on antibiotic sensitivity. 
As was suggested earlier in the introduction the most frequent ultimate 
cause of death among cystic fibrosis patients is pulmonary complications. 
Holsclaw (30) has described the nature and, briefly, the mechanism of these 
complications. Initially, such symptoms as air trapping and atelectasis are 
presented due to either partial or complete obstruction due to abnormally 
thick mucus secretions. During this time inflammatory changes take place 
from mechanical and bacterial sources, resulting in metaplasia of mucus se-
creting cells within the respiratory tract. This cycle feeds upon itself 
resulting in further damage. A complicated series of pathological changes 
then ensues at various and different times and places within the lung 
parenchyma, from bronchiectasis and frank lung-abscess to the ultimate 
events of emphysema, fibrosis, and cavitation. On the gross level, pneu-
mothorax and staphylococcal empyema, and terminally, cor pulmonale and 
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pulmonary and cardiac failure occur. 
Iacocca et al. (32) had observed, even twelve years ago, that there was 
a significantly increased prevalence in the isolation of Staphylococcus 
aureus, Pseudomonas aeruginosa and Haemophilus influenzae from sputum and 
oro- and nasopharynges of cystic fibrosis patients. Higher incidences of 
s. aureus occurred in patients not treated with antibiotics (penicillins), 
while .!.!_. influenzae was found in their study to occur with similar frequency 
before and after treatment. The incidence of R_. aeruginosa was found to in-
crease with the age of the patient, while~· aureus remained stable in its 
prevalence. Their phage typing results with S. aureus demonstrated no 
particular prevalence of any one strain, but they observed the persistence 
of specific types in each patient. The English investigators, Mearns ~al. 
(38) in a more recent study, have essentially supported the work of the 
previously mentioned investigators. However, they observed over the period 
of their study that the occurrence of ~· aureus was decreasing overall, while 
that of R_. aeruginosa was on the increase, as shown not only in the isolation 
rate, but in the serum precipitin titers as well. They had suggested that 
since the balance between the groups of patients with differing severities 
had not changed substantially, while the relative occurrence of staphylococci 
and pseudomonads had interchanged, that the two organisms have similar patho-
genic significance. This may be reflective of the trend in recent years of 
the replacement of gram positive coccal infections by gram negative rods in 
nosocomial infections, as well as the advent of better antistaphylococcal 
antibiotic therapy, this latter observation made by Doggett and Harrison (15). 
Besides these factors, it has been noted in an excellent clinical laboratory 
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review on the genus Pseudomonas by Franklin and Franklin (21), that P. 
~eruginosa possess~s extreme metabolic versatility, resistance to a wide 
variety of antibiotics and disinfectants, and tends to be distributed 
ubiquitously. both inside and outside of the hospital environment. For these 
reasons, it is also suggested that patients whose body defense systems are 
in any way compromised are rendered more highly susceptible to infection and 
pathology by this agent. The work of Doggett and Harrison (15) has been able 
to suggest further implications from respiratory tract infection by P. aeru-
ginosa. They demonstrated that serum precipitins against R_. aeruginosa were 
found only after organisms of mucoid colonial morphology were isolable from 
the sputum of cystic fibrosis patients. Contrariwise, serum precipitins were 
not found against R_. aeruginosa in patients colonized by typical, rough, non-
mucoid pseudomonas. In these cases the test antigen was obtained from the 
patients own pseudomonad. It was noted that patients with both serum pre-
cipitins against mucoid R_. aeruginosa as well as colonization by mucoid 
organisms themselves, generally have severe disease and a poor prognosis. 
This is contrasted with those patients with less severe disease who are 
colonized only by non-mucoid pseudomonas or not colonized at all. One of the 
major points in their study was that once a patient with cystic fibrosis has 
become infected and colonized with non-mucoid R_. aeruginosa, conversion to 
or replacement by the mucoid form is almost inevitable. As well, once 
colonization by mucoid R_. aeruginosa occurs, it is probably impossible to 
completely eradicate the carriage state. Finally, it was observed in their 
study that the slime from the atypical cystic fibrosis pseudomonad is dif-
ferent from that of the rarely encountered "natural" mucoid P. aeruginosa. 
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There seems to be, then, a unique relationship between the cystic fibrosis 
patient's mucus and'the alteration and adaptation made by this organism. 
The subject of the atypical P. aeruginosa has been one of considerable 
interest, particularly with respect to the nature and production of the cap-
sular slime material. The study of Schwarzmann and Boring (45) demonstrated 
a definite inhibition of polymorphonuclear leukocyte phagocytosis of certain 
bacterial species in vitro when the mixture was incubated with the atypical 
mucoid pseudomonas slime isolated from an organism isolated from a cystic 
fibrosis patient. This leads to the possible suggestion that this slime may 
well contribute to the overall lung pathology in cystic fibrosis patients in-
fected by this organism. Doggett et al. (17) found a notable difference to 
exist between the capsular slime obtained from E_. aeruginosa of cystic f i-
brosis origin and that of non-cystic fibrosis origin. The former demonstrat-
ed considerably higher viscosity as well as a marked insolubility in a mixture 
of benzene and ethanol, while the latter did not. Another point made in this 
study was that mucus obtained from various body secretions of cystic fibrosis 
patients exhibited similar properties and composition to that of the slime of 
the atypical Pseudomonas, once again strengthening the relationship of cystic 
fibrosis patients mucus to the unusual mucoid E_. aeruginosa. The composition 
of this Pseudomonas slime polysaccharide was also partially characterized in 
this study. It was found to contain some hexoses and hexosamines, and two 
prominent unknown components. In another study conducted by Linker and Jones 
(33) the composition of the atypical Pseudomonas slime was further character-
ized. It was found to contain about five percent nucleic acid and traces of 
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hexoses, hexosamines, and proteins. The main component, however, was found 
to be a substance-almost identical to alginic acid, determined both by means 
of chromatographic analysis and infra-red spectrophotometry. 
One other unique feature of this atypical, mucoid Pseudomonas has been 
observed. Linker and Jones (33) in the previously mentioned study observed 
phage plaques in the atypical organisms which had reverted to non-mucoid 
forms. The implication made here was that of a relationship of "mucoidness" 
to phage infection. Martin (34) in a more recent study has discovered that 
rings of slime were noticed to form around phage plaques of certain strains 
of P. aeruginosa. Upon subculturing of these "slime" areas, the colonies 
obtained were mucoid in nature, and the character and properties of these 
variants were identical to those of fresh mucoid isolates of ~· aeruginosa 
obtained from patients with serious chronic respiratory infections, es-
pecially those with cystic fibrosis. It seems, then, that maintenance of 
mucoidness depends upon the presence of phage in the lytic cycle in a state 
of what Martin (34) calls "pseudolysogeny". The suggestion which she has 
postulated is that persons susceptible to chronic infection by Pseudomonas 
are more liable to successive infections by a number of different strains 
of the organism, thereby increasing the chance of being colonized by a 
pseudomonad carrying that particular phage. Her postulate is consistent with 
the data obtained. 
Since this may very well be the case, the next area of interest would 
be an epidemiological survey of Pseudomonas aeruginosa. Such an investiga-
tion might give insight into nature, and mechanism of infection by this 
organism as well, possibly into the mechanism of the mucoid "conversion". 
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Doggett and Harrison (14) briefly reported the findings in their serological 
typing of Pseudomonas strains obtained from the respiratory tract of cystic 
fibrosis patients when compared with organisms derived from non-cystic 
fibrosis sources. Serotype 1 and serotypes 1 and 6 were shown to occur 
simultaneously more frequently in cystic fibrosis patients than from other 
sources. The main emphasis of this article was the suggestion that a poly-
valent vaccine be prepared and used in the prophylactic treatment of cystic 
fibrosis patients. Although no mention was made of that fact, it was 
assumed that the serological typing system used was that of Hahs (27) or a 
more recent modification thereof. Neither, here, was any mention made as to 
whether or not organisms obtained were mucoid or non-mucoid, nor was any 
suggestion made as to incidence, prevalence, or maintenance of the organism. 
In a more recent article Diaz et al. (12) made a more intensive study of 
the serological groups of !'._. aeruginosa obtained from cystic fibrosis patients. 
It was found that the majority of !'._. aeruginosa isolates from cystic fibrosis 
patients, just as those isolates from all other sources, fell into three 
distinct serological groups. Notable also was the fact that pseudomonad 
serogroups could be isolated repeatedly over periods of many months, while 
some patients showed infections by other transient serological groups. One 
of the most salient features of this study was the demonstration of identical 
0-antigens from mucoid and non-mucoid organisms obtained from the same 
patients. Another observation made by these investigators was one already 
mentioned earlier, that the increased incidence of mucoid Pseudomonas cor-
related closely with the severity of lung disease in cystic fibrosis patients. 
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Notable here was the fact that only a slight age difference existed between 
group severities •. Likewise, this age difference of persons with cystic 
fibrosis was not an important factor in the specific immune response against 
!'..· aeruginosa. This response, occurring in about 71% of the patients studied, 
occurred according to the severity and nature of the infection. Antibody 
response was found to be more frequent among patients from whom Pseudomonas 
could be isolated on more than one occasion. Supporting the observation of 
multiple types of P. aeruginosa was the fact that serum antibody titers could 
be demonstrated in somewhat less than half of 17 patients with a specific, 
demonstrable antibody response. In a still more recent study Williams and 
Govan (50) gave further supporting evidence that mucoid and non-mucoid 
pseudomonads were different forms of the same strain. This was done by means 
of pyocine typing using the system and indicator strains of Gillies and 
Govan (22) and Govan and Gillies (25) while varying the cultural milieu of 
the test or unknown strains. Although equivocal results were·obtained when 
pyocine was induced on solid cultures of both mucoid and non-mucoid pseu-
domonads obtained from the same patients, pyocin~ induced strains in liquid 
cultures demonstrated identical pyocine types of mucoid and non-mucoid 
organisms obtained from the same patient. The suggestion made for the ex-
planation of this phenomenon was simply that the slime of the mucoid colonies, 
when organisms were cultured on solid media, did not permit adequate dif-
fusion of pyocines into the medium in order for indicator inhibition to 
occur. However, in liquid-culture pyocine induction, the slime of the mucoid 
organisms was dispersed, allowing also for the dispersal of pyocines. This 
project proposes further investigation of the epidemiology of P. aeruginosa 
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by pyocine typing in the respiratory tracts of cystic fibrosis patients. 
The next area. of interest concerns a recently developed hematological 
test which assesses neutrophil function. The nitroblue tetrazolium (NBT) 
test is a means of measuring NADH and NADPH oxidase activity in polymor-
phonuclear leukocytes (PMN's). Increased activity in these enzymes is 
brought about during periods of increased phagocytic activity by these cells. 
Patriarca et al. (42) have discussed this matter in some detail. This test 
has been shown to be of particular use in the demonstration of systemic 
bacterial infections except where neutrophils are not substantially involved 
in the overall course of the disease, e.g., tuberculosis. Four substantial 
reviews and discussions of the NBT test, its use and clinical significance 
are those of Gordon and Rowan (23), Silverman and Ryden (47), Matula and 
Paterson (36), and Gordon et al. (24). Since the NBT test has been put to 
clinical use, two groups of investigators have published their findings con-
cerning the relationship of patients with cystic fibrosis and results of the 
NBT test. Sullivan and associates (48), using the unstimulated NBT test 
(the method employed which does not use exogenous agents to stimulate phago-
cytosis in the test system) reported that a significant correlation existed 
between increased NBT tests scores and presumed respiratory tract bacterial 
infections. Stable patients, on the other hand, demonstrated NBT test scores 
which fell within control limits. It was noted that NBT results could not be 
correlated with total white cell count, percentage of bands, temperature of 
the patient, or change in sputum bacterial flora. The germaine point made 
by these investigators was the contention that serial NBT testing could be 
used as a valuable adjunct in assessing response to therapy. A more recent 
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study conducted.by Hill et al. (29) supported the results and contention of 
the previous investigators, that increased NBT test results correlated 
closely with active pulmonary infection in cystic fibrosis patients. The 
evidence presented by these workers also suggested that these pulmonary 
bacterial infections caused circulating neutrophils to become more respon-
sive to chemotactic factors. 
The NBT test may be modified in such a way as to reveal two aspects of 
neutrophil function simultaneously. Not only is the test capable of assess-
ing the presence of systemically involved bacterial infections from patient 
blood samples, but when simultaneous samples are incubated with one addi-
tional component, a phagocytosis stimulating agent, such as latex particles 
or bacterial endotoxin, along with the dyes, current maximum potential NBT 
reduction by neutrophils can be observed. This is based on a percentage of 
total stimulated cells found to contain the reduced NBT dye in the form of 
dark blue-black formazan particles intracellularly. For a further discussion 
of the nature and purpose of this methodology see Windhorst~ al. (51). It 
is essential to note at this point that the NBT test results are closely and 
directly correlated to intracellular killing capacity of neutrophiles. This 
postulate was supported by Baehner and co-workers (4) and by Nathan~ al. 
(39) in studies with leukocytes from patients with chronic granulomatous 
disease. One of the potential uses of the stimulated NBT test is one of 
long term monitoring of maximum neutrophil killing capacity as reflected in 
relative NBT dye reduction. It was recently reported by Alexander and 
associates (1) that periodic variation in neutrophilic killing capacity 
occurred in all human subjects tested. The method used was the quantitative 
14 
bacterial count of ~· aureus killed after phagocytosis by neutrophils, and 
the establishment of a neutrophilic bactericidal index. This variation in 
neutrophilic killing appeared to be cyclic with a somewhat irregular periodi-
city of 14 to 24 days. In patients whose host defense was particularly com-
promised, it was found that the risk of sepsis was closely correlated to 
periods of low neutrophil bactericidal activity. Thus, although development 
of low killing capacity was not always accompanied by bacterial sepsis, 
sepsis always occurred during periods of a relatively high neutrophilic 
bactericidal index (low killing capacity). It was found, as well, in burned 
and immunosuppressed patients, that periods of low neutrophil killing activity 
were substantially lower than in control subjects. To date, one of the most 
significant applications of the stimulated NBT test has been the monitoring 
of killing capacity of the neutrophils in burned patients and the prediction 
of burn wound sepsis by NBT test results. In the study of Curreri~ al. 
(11), it was conclusively demonstrated that burn wound sepsis, measured by 
serial tissue biopsy cultures of greater than 105 organisms per gram of 
tissue, was preceded by a substantial drop of the NBT test value taken upon 
hospital admission for each patient. On the basis of a 50% drop in the NBT 
test value on admission, it was suggested that burn-wound sepsis was either 
present or imminent. One of the most salient features of this investigation 
was the observation that the occurrence of burn sepsis and decrease in ad-
mission NBT test value was not simultaneous, but in fact, significant de-
creases in NBT scores were observed to occur in several instances several days 
prior to the onset of wound sepsis. In other words, the stimulated NBT test 
could be a valuable "early-warning system" in the prediction of such a 
15 
bacterial infection. It is with this in mind that such a system may also 
be effective in predicting infections or exacerbations in the respiratory 
tracts of patients with cystic fibrosis, which are so very much a part of 
morbidity and mortality of the disease. 
Finally, it was thought to be of interest to make a simple preliminary 
study on the possible differences between mucoid variants and their own non-
mucoid revertants of ~· aeruginosa obtained from selected children with 
cystic fibrosis with respect to their antibiotic sensitivities. As was 
observed earlier, more severely afflicted cystic fibrosis patients tend to 
be colonized to a greater proportion by mucoid Pseudomonas. One speculation 
made by this investigator concerned the possibility that mucoid slime may 
somehow confer a greater antibiotic resistance upon these organisms over 
and against rough, non-mucoid forms. Thus, this factor might have a possible 
role in the overall pulmonary pathology of the disease. M.R.W. Brown (8) has 
suggested in a recent communication that much research has shown that the 
ability of ~· aeruginosa to be relatively resistant to many antibiotics is 
by a mechanism of cell surface layer exclusion chiefly at the site of the 
cytoplasmic membrane. That is to say that the various antibiotics are not 
able to penetrate into the appropriate site of action. It was thought 
with this in mind, that the possibility may exist of mucoid slime confering 
some additional antibiotic resistance to P. aeruginosa. 
MATERIALS AND METHODS 
selection of subjects. 
Altogether, a total of 28 cystic fibrosis subjects were considered in 
this study, including 13 female and 15 male patients. The age range from 
the beginning of the time of study (April 1973) was between 4 months and 19 
years of age, the mean age being 8.4 years. Eleven of these patients were 
on prophylactic maintenance dosages of various antibiotics. Seven patients 
of the total were hospitalized at least once during the one year period of 
the study. All patients were alive at the end of the study. On the basis 
of Schwachman test scores from the criteria of Shwachman and Kulczycki (45), 
the patients could be divided into three groups: mild disease (score 100-
81), moderate disease (score 80-61), and s.evere disease (score 60 or below). 
Assessment of the severity of pulmonary disease (chest x-ray results and 
pulmonary function studies) was also made on a scale of 0 to 5 (0-1, 
asymptomatic or mild; 2-3, moderate; 4-5, severe). These evaluations were 
made by Daniel G. Cunningham, M.D. at Foster G. McGaw Hospital, Loyola Uni-
versity Medical Center - Outpatient Pediatrics Clinic. For NBT test con-
trols, 6 healthy, normal controls were used ranging in age from the 
beginning of the NBT test study (October, 1973) between 2 years and 18 
years, with a mean age of 10 years. It is well to note that of the 10 
cystic fibrosis patients selected for the NBT test study the average age 
was approximately 10.5 years, the range being 1 1/2 years to 19 years. 
16 
jP 
17 
Isolation and identification of organisms. 
Specimens were taken from throat cultures, prior to which time the 
patients were requested to cough up sputum from the lungs. Culturettes 
(Scientific Products) were used. Specimens were streaked out the same day as 
collected onto 5% sheep blood trypticase soy agar (BBL), MacConkey's agar 
(Difeo), and Pseudosel agar (BBL), and incubated for 18 hr at 37°C. After that 
time the plates were observed and 3 or 4 colonies which resembled P. aeruginosa 
in odor, colonial morphology, pigmentation and "stained-glass window" hemolysis 
on blood agar, according to the criteria of Finkelstein and Punyashithiti (19) 
and King (33) were isolated and subcultured. Organisms twice subcultured 
by streaking to insure adequate isolation, were then subjected to the tests 
necessary for the identification of Pseudomonas aeruginosa, including oxi-
dative fermentation tests, malonate utilization, flagella number and place-
ment, growth at 42°C, and pigmentation, all according to the criteria of 
King (33) and Weaver (49). Isolated and conclusively identified organisms 
were then maintained as stock cultures in cystine tryptose agar (CTA) 
medium (BBL), being transferred every 6 months. It was discovered during 
the course of the study that after about one week of maintenan~e in the CTA 
medium that the mucoid organisms would usually lose their mucoid character 
irreversibly. It was subsequently discovered that the way to maintain 
mucoidness was by means of quick freezing in 1 ml aliquots of sterile de-
fibrinated sheep blood or by maintaining cultures on trypticase soy agar 
(Difeo) plates or subculturing every 48 hr as suggested by Goto~ al. (25). 
Pyocine typing 
Pyocine typing was carried out using the method recommended by Dr. Hans 
p 
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Griebel, M.D., ·of the Hines V.A. Hospital, Hines, Illinois (personal connnuni-
cation). The indicator strains employed were those of Gillies and Govan (22), 
obtained from Dr. Hans Griebel through Mr. J. T. Nickerson of Hines V.A. 
Hospital, Hines, Illinois, and those of Govan and Gillies (26) were obtained 
from Dr. Margaret G. Heckman, M.D. of Wood V.A. Hospital, Milwaukee, Wiscon-
sin. Trypticase soy broth (TSB) (Difeo) cultures of both indicator strains 
and unknown strains to be typed were incubated at 37°C for 18 hr on a Junior 
Orbit Shaker (Lab-Line). Aliquots of 0.1 ml of each indicator strain were 
transferred each to a fresh sterile 10 ml TSB and incubated by shaker culture 
at 37°C for 4 hr. After that time a lawn of each indicator strain was spread 
onto an appropriately labelled TSA plate with sterile cotton tipped appli-
cators and allowed to dry. In addition, 1 ml aliquots of each unknown pyo-
cine producing strain were transferred to fresh sterile 14 ml TSB tubes and 
were then incubated by shaker culture at 37°C for 2 hr. After that time lml 
of sterile mitomycin C (Sigma), at a concentration of 30 micrograms/ml, was 
aseptically added to each tube. After a further 3 hr incubation, cultures 
were killed by the addition of 2 ml of chloroform to each tube, and were 
shaken. Cultures were allowed to settle and the still turbid supernatant 
fluid was aseptically decanted into another smaller sterile culture tube 
and spun down in a clinical centrifuge (Clay-Adams, Co., Inc., New York, 
N.Y.) at the highest speed (6) for 15 min. A 1:10 dilution of sterile dis-
tilled water was then made of the clear supernatant. By means of a flamed 
inoculating loop of about 5 mm diameter, one drop of each culture dilution 
was applied to each of the indicator plates, flaming the loop after each 
application. The plates were allowed to dry and then incubated for 18 hr 
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at 37°c. Plates were subsequently observed and assessed for the occurrence 
of plaques on the site of drop application. Plaques were graded on a scale 
of O to 4+, 0 representing no inhibition and 4+ complete clearing. On the 
basis of the relative inhibitions of each indicator strain after at least 
two separate typing assays, the patterns were then recorded for each of the 
unknown isolates. These results were then correlated with the typing schemes 
of Gillies and Govan (22), Govan and Gillies (25) and also Heckman and co-
workers (28). 
Before each of the mucoid unknown strains was inhibited by the mito-
mycin C, loopfuls of each culture were spread each onto a TSA plate in order 
to assess whether or not each culture was indeed still mucoid. 
NBT testing 
NBT tests were carried out in the following manner. Using sterile 
lancets after swabbing the skin with isopropyl alcohol blood samples ob-
tained by finger or toe stick, or by heel stick in infants, were collected 
in heparinized Natelson blood collecting capillary pipettes (Dade). The 
pipettes were gently inverted several times before plugging one end to 
insure mixing of blood with heparin. Venous blood samples were drawn with 
the use of 5 ml heparinized vacutainer tubes (Bacton-Dickinson) using Jelco 
20 gauge disposable needles and plastic sleeves (Johnson and Johnson). The 
0 blood samples were immediately immersed in an ice water bath (0 C), unless 
the samples could be analyzed within 10 min of drawing. All samples were 
processed within 2 hr of drawing. Each 100 µl sample of blood was mixed 
with 100 µl of a stock NBT solution composed of 0.2% nitroblue tetrazolium 
Grade III (Sigma) w/v in 0.2 M sodium phosphate buffer of pH 7.4 in a 2 ml 
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disposable, conical, plastic microbeaker (Scientific Products B2713-2) and 
labelled. Into a second beaker were placed identical aliquots of 100 µl of 
blood and 100 µl of NET-buffer stock solution, but to this mixture was added 
10 µl of Difeo 0.81 latex particle solution (Difeo). Each beaker was gently 
mixed by agitation and immediately removed to a 37°C incubator for 25 min 
with a subsequent incubation for 5 min at 25°C. A portion of the super-
natant plasma was then removed with a capillary tube to concentrate the 
cells. Blood smears were then prepared on Clean, labelled glass slides and 
allowed to air dry. Slides were fixed with absolute methanol (Scientific 
Products) for 10 min and then stained in a solution composed of 1 part (dry) 
safranin 0 (Allied Chemicals), 40 parts glycerol, and 100 parts deionized 
water (w/v/v) for 10 min, and finally rinsed gently and allowed to dry. 
Slides were then examined under 1000 X oil immersion using a Zeiss 
microscope. Only neutrophils of good, distinct morphology were counted. 
In unstimulated tests (no latex) 100 cells were counted. Cells with de-
posits of blue-black crystals of formazan were counted as positive, all 
others were counted as negative. In stimulated tests (with latex particles) 
100 cells were counted and these were grouped into two categories, depending 
on the number of particles within the cell and the amount of formazan depos-
it: 1) cells containing 5 or more latex particles without dye reduction 
(negative) and 2) cells containing 5 or more latex particles with dye 
reduction (positive). 
Antibiotic sensitivity testing 
Antibiotic sensitivity testing was carried out by tube dilution method 
(41). Two mucoid strains and their respective non-mucoid revertants of 
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p, aeruginosa were employed in this study. The first, PZ M20, was obtained 
from a severely ill cystic fibrosis patient, and the second, KN Mll, from a 
patient with mild disease. The antibiotics selected for use were reagent 
grade for laboratory use only. They were disodium carbenicillin (Roerig), 
tobramycin (Lilly), gentamycin sulfate (Schering) and sodium colistimethate 
(Warner-Chilcott). Sterile serial two-fold dilutions were made in brain 
heart infusion (BHI) broth (Difeo) of each antibiotic beginning with 800 
µg/ml disodium carbenicillin, 100 µg/ml tobramycin, 200 µg/ml gentamycin 
sulfate, and 12306 µg/ml sodium colistimethate. A total of 8 serial 
dilutions were made from the first tubes, while the final tenth tube served 
as a control containing no antibiotic. Equal volumes of a 10-4 dilution in 
0 BHI broth of a 37 C, 18 hr culture of each organism were added, to each 
appropriate tube, that is one culture for each series of 10 tubes for each 
of the 4 antibiotics. (Each of the 10-4 dilution inocula gave readings of 
nearly 0 absorbance when compared to appropriate controls, on a Spectronic 
20 (Bausch and Lomb) spectrophotometer.) This effected a final 2-fold 
dilution of the antibiotics in each tube. Tubes were incubated at 37°C for 
18 hr and then observed macroscopically for growth inhibition. The MIC was 
considered to be the concentration of antibiotic in the first tube showing 
no visible turbidity. After observation, loopfuls of the contents of the 
MIC tube and the following tube were plated out onto BHI agar to check for 
adequate purity and homogeneity of organism, as well as whether or not 
reversion of mucoid to non-mucoid form had taken place. The experiment was 
performed in triplicate for disodium carbenicillin and in duplicate for all 
other antibiotics. 
Limulus lysate endotoxin assay 
;:.:::::;--
The Limulus amebocyte lysate assay for endotoxin was performed on 
several lots of 5 ml heparinized vacutainer tubes (B/D-lots 8113927, 
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8113238, and 8113689), on one lot of Micro-Natelson blood collecting tubes 
(Sherwood - lot 36031), on one lot of Micro-Caraway blood collecting tubes 
(Sherwood - lot 25631), and finally on two lots of Natelson blood collecting 
pipettes (Dade - lots 197H and 197B), which were those used in the NBT test. 
The Limulus assays were graciously performed by J. Robinson, M.D. of Hines 
v.A. Hospital, Hines, Illinois. The method employed was that of J, Levin, 
M.D. of John Hopkins Hospital, Baltimore, Maryland. The estimates of the 
amount of endotoxin inside the tubes were expressed in a semiquantitative 
fashion on a scale from 0 to 4+. 
All other reagents used, when not specified, were obtained from 
Fisher Scientific. 
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RESULTS 
survey of patient status 
An expression of overall patient status considered from the end of the 
study is to be found in Table 1. From these data, patients were assigned 
into three arbitrary groups based on Shwachman scores mentioned in the 
Materials and Methods section. With no significant exceptions, the severity 
of pulmonary status correlated well on an individual basis with the Shwach-
man Index (index of overall severity), thereby facilitating categorization. 
Most of the patients' overall conditions remained stable throughout the 
study, with only two exceptions. Patient DH demonstrated a marked improve-
ment in her overall condition early in the study, allowing the change in 
assessment from severe status to moderate status to occur prior to parti-
cipation in the NBT testing. Patient PZ demonstrated a more or less steady 
decline in overall status during the study, allowing for the status to 
change from severe to more severe. Patients hospitalized for pneumonia 
during this study were the following: TrH - once, TH - twice, DH - once, 
SI - 5 times, TS - once, PW - once and PZ - three times. 
Results of the survey for ~· aeruginosa 
The results of this survey demonstrate the occurrence of P. aeruginosa 
among patients with cystic fibrosis. Incidence of infection by mucoid and 
non-mucoid organisms, and by different pyocine types is correlated with 
severity of disease. To begin, a compilation of all cultures obtained from 
the 28 cystic fibrosis patients was made (Table 2). Here is expressed the 
total number of cultures by source, e.g., throat, nose, sputum, etc., as 
well as the number of isolates from which P. aeruginosa was isolated. Note 
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TABLE 1 
Survey of overall cystic fibrosis patient status. 
Patient Sex Birth Shwachman* Average Pulmonary + 
'i<* Date Index Status 0 - 5 
LF F 7 /20/71 96 0 
SC M 3/ 7 /71 95 0 
GG M 4/ 8/59 93 1 
LC F 7/ 2/59 92 0 
CB M 7/ 9/67 85 0 
KN M 5/ 2/61 82 3 
JF F 9/21/65 81 1 
TM M 5/ 6/67 81 1 
RMW F 7/ 5/61 81 3 
MBQ F 7/12/65 79 2 
TS M 10/29/55 77 3 
SK M 8/26/71 76 1 
DP F 7/ 3/66 74 3 
cc F 8/26/65 72 3 
SW M 10/ 1/68 72 1 
KL F 12/ 3/61 71 3 
DR M 10/16/72 71 2 
DH F 3/ 7/54 68 3 
AH M 6/14/70 68 0 
JB F 7/ 8/64 67 3 
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TABLE 1 (CONTD.) 
* Average Pulmonary+ patient Sex Birth Shwachman 
Date Index Status 0 - 5 ** 
RW M 8/27/65 67 2 
MT F 5/25/59 65 4 
PW M 4/ 8/65 61 3 
TH M 11/16/57 55 4 
BW M 11/13/71 53 4 
SI M 4/ 3/72 52 3 
TrH F 4/26/57 44 5 
PZ F 7/23/65 30 5 
** 0 - Normal 5 - Severe 
* Score 81 - 100 Mild Disease 
Score 61 - 80 Moderate 
Score 60 or below Severe 
+ Radiographic data only 
P' 
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TABLE 2 
Total number of cultures obtained from cystic fibrosis patients reflecting 
prevalence of respiratory tract infection by R_. aeruginosa. 
Patients Date Source Total no. No. positive Pseudo-
first cultures monas isolates (M, 
culture N & N, N)+ 
performed 
CB 5/ 8/73 Throat 17 None 
" 11/ 6/73 Nose 4 None 
JB 6/26/73 Throat 8 7N 
II 11/19/73 Nose 4 1 N 
cc 9/25/73 Throat 1 1 M & N 
LC** 4/23/73 Throat 1 None 
SC 5/ 8/73 Throat 6 " 
" 1/ 6/73 Nose 1 1 N 
LF;~* 11/20/73 Throat 1 None 
" 11/20/73 Nose 1 " 
JF 1/23/74 Throat 1 1 N 
II 1/23/74 Nose 1 None 
TrH 6/12/73 Throat 12 11 M, 1 N & M 
" 1/ 9/74 Nose 1 None 
TH 5/ 8/73 Throat 14 13 M, 1 N & M 
" 10/20/73 Nose 2 2 M 
" 10/20/73 Sputum 1 1 M 
DH 5/15/73 Throat 14 10 M, 1 N & M, 
1 N 
" 11/27 /73 Nose 3 None 
AH 4/16/73 Throat 4 None 
II 11/ 6/73 Nose 2 " 
SI 4/16/73 Throat 14 12 N 
" 10/30/73 Nose 5 2 N 
" 1/15/74 l/Ear 1 None 
SK 5/ 8/73 Throat 7 3 N 
II 12/ 3/73 Nose 1 None 
KL 8/28/73 Throat 3 2 M & N, 1 M 
II 10/30/73 Nose 2 2 M 
TM 4/16/7 3 Throat 7 None 
" 11/20/73 Rf Ear 4 II 
II 11/20/7 3 Nose 2 " 
" 4/16/73 L/Ear 1 " 
KN 5/22/73 Throat 4 4 M & N 
II 1/29/74 Nose 2 None 
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TABLE 2 (CONTD.) 
patients Date Source Total no. No. positive Pseudo-
first cultures monas isolates (M, 
culture N & N, N)+ 
performed 
DP** 12/27 /73 Throat 1 None 
" 12/27/73 Nose 1 " 
MBQ 5/ 8/73 Throat 5 3N 
If 10/ 30/72 Nose 2 None 
DR 6/26/73 Throat 13 6 N 
" 8/28/73 Nose 3 None 
TS 11/13/73 Throat 2 2 M 
" 11/13/73 Nose 2 2 M 
If 11/13/73 Sputum 1 1 M 
ws** 4/25/73 Throat 2 None 
MT 11/ 6/73 Throat 13 5 N 
" 11/ 6/73 Nose 2 None 
PW 6/ 4/73 Throat 14 14 M 
If 12/11/73 Nose 2 None 
RW 4/16/73 Throat 5 1 N, 3 N & M, 
1 N 
RW 10/30/73 Nose 2 None 
RMW 6/ 5/73 Throat 11 1 N, 9 N & M 
" 12/19/73 Nose 2 None 
BW 4/25/73 Throat 6 5 N, 1 N & M 
II 12/27/37 Nose 2 1 N 
PZ 4/25/73 Throat 13 12 M, 1 N & M 
" 12/20/73 Nose 3 2 M, 1 N 
** These patients had routinely shown negative throat and sputum cultures 
for P. aeruginosa prior to this study. 
+ M mu co id 
N - non-mucoid 
M+N 
- both mucoid and non-mucoid 
, 
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~as made also of the occurrence of mucoid and non-mucoid organisms. Dates 
of first cultures were noted to indicate .the length of participation of each 
patient in the study. A very significant proportion of these patients 
(71.5%) were found to be infected by R_. aeruginosa (Table 3). A further 
concern was to break down the data on the occurrence of Pseudomonas in in-
fected patients into the prevalence of both non-mucoid and mucoid organisms 
(Table 4). From the results presented thus far, an attempt was made to 
correlate the prevalence of f_. aeruginosa with Shwachman scores (clinical 
severity of cystic fibrosis) (Table 5). Each horizontal row represents the 
total number of patients in that particular Shwachman score, rank, i.e., 
severe, moderate or mild. Each vertical column indicates the state of P. 
aeruginosa infection whether absent, present and demonstrating mucoid forms 
with or without non-mucoid forms, or present and demonstrating non-mucoid forms 
only. The percentage indicated next to each number represents the percentage 
of patients in each respective "severity" group which are infected or not by 
P. aeruginosa. The rest of the results of the f_. aeruginosa survey are con-
cerned with Pseudomonas pyocine typing of f_. aeruginosa isolates and their 
occurrence in infected patients with cystic fibrosis, the relationship to 
type and colonial morphology the consistency and variability of pyocine 
typing results. All cystic fibrosis patients' Pseudomonas isolates which 
were pyocine typed, as well as the date each culture was isolated and the 
colonial morphology of the organism at the time of isolation, i.e., mucoid 
(M) or non-mucoid (N) are listed in Table 6. Then, the occurrence of each 
pyocine type or types in the case of multiple R_. aeruginosa infection, with 
the number of patients harboring that (those) type(s), along with the ages of 
each patient was ranked (Table 7). The prevalence of mucoid and non-mucoid 
TABLE 3 
Prevalence of respiratory tract infection 
by R· aeruginosa in cystic fibrosis patients. 
Non-infected 
Infected 
Total 
Number 
8 
20 
28 
% 
28.5 
71.5 
100.0 
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TABLE 4 
Prevalence of mucoid and non-mucoid strain respiratory 
tract infection of P. aeruginosa in cystic fibrosis patients. 
Infection by: Number lo 
Non-mucoid alone 8 40 
Mucoid and non-mucoid 9 ] 45 J 12 60 Mucoid alone 3 15 
Total 20 100 
30 
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TABLE 5 
Correlation of Shwachman Index with the occurrence of 
mucoid and non-mucoid forms of R_. aeruginosa in 
cystic fibrosis patients. 
Number of Patients 
Shwachman Relative Infected by Infected index severity Non- non-mucoid by 
* 
range of disease infected forms only mucoid forms Total 
100 - 81 Mild 5 (62.5%) 2 (25%) 1 (12.5%) 8 (100%) 
80 - 61 Moderate 3 (20%) 5 (33%) 7 (47%) 15 (100%) 
60 and below Severe 0 (0%) 1 (20%) 4 (80%) 5 (100%) 
* This list includes both patients colonized by mucoid forms alone as 
well as those colonized with both mucoid and non-mucoid forms. 
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TABLE 6 
Total number of pyocine typed positive f. aeruginosa throat culture 
Patient 
JB 
II 
II 
II 
cc 
SC 
JF 
TrH 
II 
II 
II 
" 
TH 
" 
" 
II 
DH 
" 
II 
" 
" 
SI 
" 
II 
II 
II 
SK 
II 
KL 
II 
II 
isolates which were obtained from cystic fibrosis patients. 
Date specimens 
originally obtained 
11/19/73 
1/ 4/74 
3/12/74 
4/ 2/74 
10/13/73 
4/26/74 
1/23/74 
6/12/74 
7/10/74 
7 /31/ 74 
9/11/74 
1/ 9/74 
5/ 8/73 
6/19/73 
11/20/73 
1/ 4/74 
5/22/73 
8/ 3/73 
9/18/73 
11/20/73 
3/12/74 
4/19/73 
10/ 8/73 
11/20/73 
1/ 4/74 
1/29/74 
6/19/74 
6/25/74 
8/28/73 
11/20/73 
12/26/73 
+ Pyocine type 
2F (N), UT# (N) 
II 
UTI! (N) 
2F (N), UT# (N) 
VA39C (M), 3E (N) 
** lB (N) 
ucllll (N) 
VA39C (M) 
II 
II 
VA39C (M)' UT 11 CM) 
II 
3E (H) 
3E (M)' 3E (N) 
3E (M) 
3E (M)**, 3E (N) 
3E (M) 
II 
" 
" 
" 
3E (N) 
lB (N) 
LB (N) , UT// (N) 
3E (N) 
lB (N)' 3E (N) 
UTI! (N) 
II 
2F (M)' 2F (N) 
3E (M)' 3E (N) 
3E (M) 
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patient Date specimens Pyo cine type + 
originally obtained 
KN 5/22/73 UT/t (M)' UT/t (N) 
" 10/10/73 UT/I (N) 
" 4/ 2/73 UT/I (M)' UT If (N) 
MBQ 5/ 8/73 UT/I (N) 
" 1/ 5/74 II 
DR 6/25/73 lB (N) 
" 8/20/73 " 
" 10/10/73 
" ,, 1/ 9/74 
" 
TS 11/20/73 UT/I (M) 
" 12/19/73 II 
MT 11/20/73 lC (N) 
PW 6/ 4/73 3E (M)' 3E (N) 
" 10/10/73 3E (M) 
" 12/19/73 3E (M)' 3E (N) 
RW 4/10/73 lB (N)' 3E (N) 
" 5/ 8/73 3E (M) 
" 6/19/73 3E (M)' 3E (N) 
" 10/30/73 3E (M)' 3E (N) 
" 12/26/73 3E (M)' 3E (N) 
RMW 6/ 5/73 UT/I (M)' UT/I (N) 
" 9/25/73 II 
" II 12/26/73 UT# (N) 
3/ 1/74 UT/I (M), UT/I (N) 
BW 6/ 5/73 lB (N)' UT/I (N) 
" 7/24/73 lB (N) II 12/27/73 3E (N) 
PZ 4/25/73 UC/Ill (M) 
" 6/19/73 II 
" 8/28/73 II 
II 12/26/73 uclflf (M) ' uclflf (N) II 1/ 4/74 ucllll (M) 
" 4/ 2/74 UC/Ill (M) , uc1111 (N)' .3E (M) 
+ M - mucoid N - non-mucoid 
** Nasal isolates included 
If UT - untypable lffl UC - unclassifiable 
p 
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TABLE 7 
Carriage of single and multiple pyocine types of E_. aeruginosa in 
respiratory tract infections of patients with cystic fibrosis. 
Pyocine Type(s) Number of Patients *Ages of Patients 
in each group 
UT+ 5 2.5 yr, 2 (13 yr), 
8 yr, 18 yr 
3E 3 9 yr, 16 yr' 20 yr 
lB 2 1. 5 yr, 3 yr 
lB, 3E, UT+ 2 2 yr' 2.5 yr 
lB, 3E 1 5 yr 
lC 1 15 yr 
2F, 3E 1 12 yr 
2F, UT+ 1 9 yr 
VA39C, UT+ 1 17 yr 
VA39C, 3E 1 8 yr 
uc**, 3E 1 9 yr 
** UC 1 8 yr 
TOTAL 20 
* Calculated from the end of the study. 
** Unclassifiable. 
+ Untypable. 
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colonial morphologies of original Pseudomonas isolates was then correlated 
to each of the respective strains' pyocine types (Table 8). In this table, 
too, it is to be noted that the totals for each pyocine type are obtained 
by including organisms isolated from each patient regardless of the source 
of isolation, e.g., throat culture, sputum, nose, etc. Correlating the 
above data, a number and percentage distribution of each pyocine type among 
infected patients is shown (Table 9). In the final two tables of this 
section, an example of inherent variability is shown in serial pyocine 
typing in one strain (SI 8) of a clinical isolate of P. aeruginosa (Table 10). 
These variable isolates were obtainable from only 2 of the 20 infected 
patients. A more representative example of consistent serial pyocine typing 
results is shown using the single isolate (DR 8) (Table 11). This repro-
ducibility was more characteristic of the rest of the typable P. aeruginosa 
isolates. 
Nitroblue tetrazolium (NBT) testing 
Stimulated and unstimulated nitroblue tetrazolium (NBT) testing was 
performed serially on 16 subjects including both cystic fibrosis patients 
and control subjects. These results are expressed both graphically as 
serial test results obtained over a period of time (Fig. 1-3) and also as 
average NBT test results among severe and moderate to mild cystic fibrosis 
patient categories and control subjects, All NBT test results indicated 
in Fig. 1-3 were obtained using capillary blood samples only. All extra 
pertinent information is indicated on each graph at the time of its 
occurrence. The serial NBT test results of cystic fibrosis patients falling 
in the severely affected range (Shwachman scores of 60 or less) are shown 
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TABLE 8 
The relationship of pyocine type to mucoidness or non-mucoidness of 
P. aeruginosa obtained from cystic fibrosis patients. 
pyocine type Mu co id Non-mucoid Total+ 
lB 5 5 
lC 1 1 2 
2F 1 2 3 
3E 5 6 11 
VA39C 1 1 2 
1 1 2 
**uT 4 7 11 
* Unclassifiable pattern of inhibition (Inhibition of type E only). 
**untypable on the basis of no inhibition of any indicator strains. 
+Totals for each type are obtained by taking the overall occurrence of 
each type from individual patients regardless of source. 
I 
. I 
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TABLE 9 
Occurrence of each pyocine type with regard to the total number 
of pyocine-typed isolates obtained from the 
20 infected cystic fibrosis patients. 
Pyocine type Number of isolates for each 
* 
+ 
3E 
lB 
2F 
uc* 
VA39C 
IC 
TOTAL 
Number 
9 
9 
5 
2 
2 
2 
1 
* 30 
pyocine type 
Percent 
30.0 
30.0 
16.6 
6.7 
6.7 
6.7 
3.3 
100% 
The discrepancy between this number and that of the total number of 
patients (20) lies in the fact that 6 patients were infected with 2 
different strains each, and 2 other patients were infected with 3 
strains each. 
UT - untypable. 
-++ UC - unclassifiable. 
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TABLE 10 
Example of the variability of pyocine typing results in 
repeated trials using the same clinical isolate of 
P. aeruginosa designated SI 8. 
~'( 
Trial Relative strength and pattern of indicator inhibition 
number 
El E2 E3 E4 ES E6 E7 ES 6A 6B 6c 6D 6E 
1 2.5 4 2.5 2 3.5 0 2.7 0 0 4 4 2.5 2. 5 
2 4 4 4 1. 5 4 0 4 0 0 4 4 0 4 
3 4 4 4 3 4 0 4 4 1 4 4 2 4 
4 4 4 2.5 0 3 0 3 3 0 4 4 2 4 
5 4 4 2 1 4 0 4 3 0 4 4 2 4 
Average 
results 3.7 4.0 3.0 1. 5 3.7 0 3.5 2.0 0.2 4.0 4.0 1. 7 3.7 
+ + + + + + + + 
These relative average results correspond to the Gillies and Govan pyocine 
types E3, having selected, somewhat arbitrarily, any average value of 2.0 
or less as a negative result. 
~'; 
0 indicates no inhibition, 4 indicates complete inhibition. 
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TABLE 11 
Example of consistent pyocine typing results in repeated trials using 
the same clinical isolate of P. aeruginosa designated DRS . 
Trial .,·~ Relative strength and pattern of indicator inhibition. 
number 
El E2 E3 E4 ES E6 E7 ES 6A 6B 6c 6D 6E 
1 2 4 2.5 3 3 2 4 3.5 2 3.5 3 
2 4 4 3 4 2.5 4 3.5 4 2.5 4 3 
3 4 4 4 4 4 4 4 4 3 4 3 
4 4 3.5 3 4 4 4 3 4 2.5 4 3 
Average 3.5 3.9 3.1 3.S 3.S 3.5 3.6 3.9 2.5 3.9 3.0 
results 
+ + + + + + + + + + + 
These relative average results correspond to the Gillies and Govan pyocine 
type lB. 
* 0 indicates no inhibition, 4 indicates complete inhibition. 
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Fig. 1. Serial stimulated and unstimulated NBT test results 
of four subjects (a - d) with severe cystic fibrosis 
disease. 
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Figure le 
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Fig. 2,. Serial stimulated and unstimulated NBT test results of 
six subjects (a - f) with moderate to mild cystic 
fibrosis disease. 
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Figure 2c 
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Figure 2~ 
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Figure 3c 
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in Fig. 1, while the results of the moderately to mildly affected group of 
cystic fibrosis patients (Shwachman scores of 61 or greater) are presented 
in Fig. 2. The NBT test results of the control subjects are shown in Fig. 3. 
Subjects TrH (Fig. 3d) and KH (Fig. 3f) are half-siblings of different cystic 
fibrosis patients. A compilation of all unstimulated and stimulated NBT test 
results are shown in Fig. 4 and 5, respectively. These results include not 
only those patients who participated in the serial NBT test study (Fig. 1-3), 
but include other subjects on whom occasionally NBT tests were performed. 
Z-score tests were used for the statistical analysis of the NBT test scores 
of Fig. 4 and 5, instead of the Student's T test because of the size of each 
sample. These results are presented in Table 12. In it are compared the con~ 
trol groups and two cystic fibrosis patient groups according to ther respec-
tive stimulated or unstimulated NBT test result category. Differences between 
simultaneously drawn capillary and venous blood stimulated NBT tests were then 
compared (Fig. 6). In Fig. 6a blood from cystic fibrosis patient TH (Shwach-
man score 55) was drawn on two separate occasions one week apart and compared 
(Trials 1 and 2). In Fig. 6b blood from a control (non-cystic fibrosis) 
subject, BZ, was employed as above. The effects of two different pre-incuba-
tion temperatures on NBT test results was shown (Fig. 7). Capillary blood 
samples from a control subject, PVG, were kept for various periods of time be-
fore mixing and incubation with the NBT dye solution and/or latex particles. 
Limulus lysate-endotoxin assay results 
The Limulus lysate-endotoxin assay, which was performed by passing 1 ml 
amounts of endotoxin free distilled water through each individual tube, showed 
a 4+ positive result for the presence of endotoxin in every tube. This is to 
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Figure 4 
Unstimulated NBT test results of severe, and 
moderate to mild cystic fibrosis patients, and control subjects. 
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Figure 5 
Stimulated NBT test results of severe, and 
moderate to mild cystic fibrosis patients, and control subjects. 
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TABLE 12 
Z-Score tests for assessing significance of correlation between 
the three separate averages each of 
stimulated and unstimulated NBT test values. 
z = 
UNSTIMULATED 
I 
(Severe CF) 
49.2 
27.0 
37 
II 
(Mod. -Mild CF) 
33.4 
21.8 
42 
III 
(Control) 
12.7 
15.0 
31 
STIMULATED 
A B C 
(Severe CF) (Mod.-Mild CF) (Control) 
82.1 81. 0 73.7 
34.3 14.7 14.4 
37 42 31 
AVERAGES COMPARED Z-SCORES SIGNIFICANCE 
I - II 2.8 Significant difference at 1% level. 
I - III 7.1 Significant difference at 1% level. 
II - III 4.8 Significant difference at 1% level. 
A - B 0.2 No significance at 5% level. 
A - c 1.4 No significance at 5% level. 
B - c 2.1 Significant difference at 1% level. 
.. 
.. 
.. 
-
~ig. 6, A comparison of stimulated capillary and 
venous blood NBT values in a subject (TH) 
with severe cystic fibrosis disease (6a) or 
in control subject (BZ) (6b). (Samples were 
drawn within five minutes of each other). 
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Trial 1 Trial 2 
Venous Blood 
Trial 1 Trial L 
Venous Blood 
.. 
.. 
.. 
.. 
Fig. 7. Stimulated and unstimulated capillary blood NBT 
test values for samples preincubated at 34°c (7a) 
or o0 c (7b). U, unstimulated NBT value; S, 
stimulated NBT value; T, preincubation period. 
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say that these results roughly corresponded to the positive control of 1 µgm 
endotoxin/ml. A listing of these tubes once again is as follows: 3 tubes 
each of Lots number 8113927, 8113238, and 8113689 Becton-Dickinson 5 ml 
heparinized Vacuta~er tubes; 5 each of 2 lots, 197H and 197B, of Natelson 
blood collecting pipettes (Dade); and 5 each of one lot, number 36031, of 
Micro-Natelson blood collecting tubes (Sherwood), and one lot, number 25631, 
of Micro-Caraway blood collecting tubes (Sherwood). 
Antibiotic sensitivity testing 
Antibiotic sensitivity testing results are to be found in Table 13. 
The minimum inhibitory concentration (MIC) of each antibiotic against the 
two mucoid strains of K· aeruginosa and their respective non-mucoid 
revertants is indicated in µgm/ml of each antibiotic. It is interesting to 
note that partial reversion from mucoid to non-mucoid occurred during the 
course of each trail only of strain KN Mll being tested against sodium 
colistimethate (Warner-Chilcott). 
I 
J 
SS 
TABLE 13 
Minimum inhibitory concentrations (MIC's)* of various antibiotics for 
mucoid strains of two clinical R_. aeruginosa isolates KN Mll and 
PZ M20 and their respective non-mucoid revertants. 
Mucoid Non-mu co id Mu co id Non-mucoid 
Antibiotics Trial KN KN PZ PZ 
Number M 11 M 11 M 20 M 20 
Di sodium 1 so 50 100 25 
carbenicillin 
2 50 25 100 25 
3 50 100 100 100 
Tobramycin 1 0.8 0.8 0.4 0.4 
2 0.4 0.4 0.4 0.4 
Gentamicin 1 1. 6 3.2 1.6 0.8 
sulfate 
2 0.8 0.8 0.8 1. 6 
Sodium 
colistimethate 1 1.0 1.0 1.0 1.0 
2 0.5 1.0 0.5 0.25 
* MIC's expressed as µg/ml. 
I 
l 
' 1 
' '
' 
I 
I 
J 
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DISCUSSION 
The genetically determined disease cystic fibrosis is one whose compli-
cations include severe respiratory obstruction by presumably viscid mucus 
and subsequent bacterial infections of .!?_. aureus and with ever increasing 
frequency, f. aeruginosa. It was in that interest that this study was under-
taken, namely to follow the incidence and prevalence of f. aeruginosa by 
characteristic colonial morphologies (mucoid and non-mucoid) and by pyocine 
type, to observe the serial stimulated and unstimulated NBT test results in 
cystic fibrosis patients and control subjects, and finally to observe 
whether or not mucoidness of the colonial morphology of P. aeruginosa 
affected antibiotic susceptibility of that organism. 
The 28 cystic fibrosis patients studied represent a heterogeneous group 
with regard to age, sex, and severity of overall status including pulmonary 
status (Table 2). Also, there is a definite correlation between overall 
patient status as measured by the Shwachman score and respiratory tract infec-
tion with!:_. aeruginosa (Tables 2-5). Of the 28 patients studied, 20 (71.5%) 
harbored pseudomonads (Table 3). Twelve of these 20 (60%) had organisms with 
mucoid colonial morphology (Table 4). It can readily be seen in Table 5, 
which correlates the severity of cystic fibrosis patients' status with the 
occurrence of P. aeruginosa of both mucoid and non-mucoid colonial morpho-
logies, that the mildly affected group is predominantly not infected by any 
Pseudomonas (62.5%). Moderately affected patients show a wider distribution 
among the three infection status categories. Finally, the severely affected 
56 
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patients demonstrate a remarkably high infection rate by mucoid P. aerugi-
nosa (80%). These results are in basic agreement with those of Doggett and 
Harrison (15), whose findings demonstrated that patients with serum preci-
pitins against R_. aeruginosa and colonization by mucoid forms have a poorer 
prognosis than those patients with no serum precipitins and colonization by 
only non-mucoid organisms. 
The results of the pyocine typing study are shown in Tables 6 through 
9. Table 6 is a compilation of Pseudomonas pyocine types of all R_. aerugi-
nosa isolates which were tested. Although the distinction is not indicated 
in the table, identical Pseudomonas pyocine types were obtained from nose 
cultures as those obtained from throat cultures from patients TH (2 times, 
pyocine type 3E), SI (one time, pyocine type 3E), TS (2 times, pyocine type 
UT), and PZ (2 times, pyocine type UC). As can be seen from this table, the 
I pyocine type of strains isolated from each patient remains fairly constant, 
I 
! 
even for patients who harbor more than one pyocine type, with the exception 
of patients KL and BW, whose pyocine types were entirely different from 
isolation to isolation. Among the rest of the cystic fibrosis patients who 
were colonized by multiple types, the different types could be isolated 
either serially, as in the example of patient SI, or concomitantly as in the 
cases of patients TrH and JB. These observations are supported also by the 
j 
I 
work of Diaz and Neter (12) in their study of the serogroups of P. aeruginosa 
in infected cystic fibrosis patients. 
1 
Two important observations were made during the present pyocine typing 
study. In Table 7, the serial pyocine typing patterns are illustrated for 
just one strain, SI 8, of a P. aeruginosa isolate. A great variability was 
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found not only in this one isolate, but in all isolates of pyocine type 3E 
obtained from patient SI. All other pyocine types obtained from all other 
infected patients displayed a much greater stability. Such an example is 
to be found in Table 8. The single strain DR8 was serially typed on four 
different occasions and on each typing the relative inhibitions of each 
respective indicator strain were virtually the same. Chadwick (9) has also 
observed this phenomenon, but by typing serial isolates from the same site 
in the same patient, rather than serially typing single isolates. His 
suggestion is simply that the same organism may in fact be producing pyo-
cines which may somehow be more labile or unstable under slightly varying 
conditions or that perhaps the indicator susceptibility may also change 
during serial typing. Either or both of these factors may be involved in 
the variability of the patterns of inhibition. The present study tends to 
support these possible mechanisms more directly by demonstration of the 
varying results with the same organism. 
The other important observation to be noted is that during the course 
of the serial pyocine typing of all mucoid isolates of P. aeruginosa, no 
change in the pyocine typing pattern of any isolate could be observed during 
conversion from the mucoid to the non-mucoid state. This observation was 
also supported to a certain extent by Williams and Govan (50) who observed 
that mucoid and non-mucoid pseudomonads isolated from the same cystic 
fibrosis patient were of identical pyocine types. They thought that these 
mucoid forms might merely be variants of the same non-mucoid strain. The 
demonstration in this current study of identical pyocine types in mucoid 
organisms and their own respective non-mucoid revertants, as well as in the 
originally non-mucoid clinical isolates further supports this contention. 
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Three pyocine types collectively predominated in the upper respiratory 
tract infections o~ cystic fibrosis patients in this study (Table 9). These 
types, UT, 3E, and lB, occurred either alone, together, or in coexistence 
with other types in 18 (90%) of the 20 infected patients. These three types 
were found to be the predominant infecting strains, with the non-pyocine 
producing strains UT and 3E comprising 160% of the infecting strains (Table 
10). With the exception of the somewhat higher percentage of type UT 
strains, the results of the present study are similar to those of other 
workers. In the results of their experience with pyocine typing of I· 
aeruginosa isolates in a midwestern Veterans Administration Hospital, 
Heck.man et al. (28) found that type 1 constituted 52% of the total isolates, 
followed by an untypable strain (12%), type 10 (11%), type 3 (7%) and 
type 5 (3%). The rest of the strains consisted of miscellaneous types, 
variable types and new types not described previously by Gillies and Govan 
(22). In their s~udy of.!'._. aeruginosa infections in a general hospital, 
it was found by Baltch and Gr,iffin (5) that 31% of the typable organisms 
were of type 1, type 5 comprised 12%, type 3, 10% and type 10, 8%. Of the 
total number of isolates (238), 21 (9%) were found to be untypable. Con-
sidering the vast proportion of pyocine type 1, the Govan and Gillies 
pyocine subtyping system was most useful in further differentiating that 
type in particular. In their study (25) types lB, lC and lD comprised 
about 74% of th~ total type 1 strains, and are represented in their decreas-
ing order of prevalence. It is well to note again that types lB and lC were 
the only two type 1 strains found, with type lB heavily predominating. 
I 
I 
I 
I 
I 
I 
I 
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One interesting observation made in the present study that has not 
previously been documented in the literature, has led to a suggestion as to 
the possible "order" of infection by different pyocine types of K_. aeruginosa 
in patients with cystic fibrosis. It was noted from the results of Table 9, 
that although not all very young patients (3 years or less) were infected 
with type lB, this type was found to infect only those patients who were 
three years of age or less. Another fact was that none of the type lB 
strains obtained from any of the infected patients were found to be mucoid 
(Table 9). Of the five patients infected by this type lB, three of these 
(SI, RW, and BW) were infected by other strains as well. The cases of RW 
and BW are particularly interesting in that both of these patients were 
initially infected with the non-mucoid type lB, with or without concomitant 
infection by other types. Through the course of this study, both of these 
patients developed infections by mucoid strains of K_. aeruginosa, and in the 
case of patient RW, the type lB strain was probably completely eliminated in 
favor of the mucoid type 3E. This "elimination" phenomenon has not been 
observed in any other patients. However, indirect evidence suggests that 
pyocine type lB cannot successfully compete with other strains of P. 
aeruginosa which eventually convert to a mucoid form. Thus, no type lB has 
been observed in older patients and this type is apparently unable to convert 
to the mucoid form (Table 11). Another possible explanation of this occur-
rence is one in which.certain strains of,!'._. aeruginosa may produce pyocines 
active against other strains, thereby inhibiting their growth in simul-
taneous culture or i.nfection. This postulate has yet to be further docu-
mented. 
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f Since it has been demonstrated that a certain group of pyocine types 
tend to be the predominant infectious agents, the question arises as to the 
possibility of preparing polyvalent Pseudomonas vaccines for use in eliciting 
protective antibody response in cystic fibrosis patients. In the work of 
other investigators, particularly that of Alexander et al. (2) with burn 
patients, and that of Young et al. (52) with cancer patients, successful 
results have been obtained in producing effective protective immune response 
in these patients against.!:_. aeruginosa. In both of these studies, the most 
dramatic results were the decrease in mortality due to the infection by 
P. aeruginosa rather than a decrease in the infection rate itself. 
The results of serial NBT testing as stated previously in the Results 
section are to be found in Fig. 1-3. Of the first four figures (Fig. la-d), 
three represent patients who were hospitalized for pneumonia during the 
course of the NBT testing: PZ, TH, and SI. The points of hospital admission 
and discharge are indicated on each graph. Also indicated was the duration 
of a severe exacerbation of respiratory symptoms in patient TH. The graphs 
of these three patients are particularly interesting in light of the con-
siderable lowering of unstimulated NBT test results during or following 
each hospital admission, when compared to each respective admission value. 
Except in the case of patient PZ (the most severely affected of all cystic 
fibrosis patients studied - Shwachman index 30), the stimulated values fell 
simultaneously with the unstimulated test results. These results correlate 
quite well with the improvement in over.all condition of each patient during 
the hospitalization. The results of this study correlate well with those 
of Sullivan and associates (48) in their serial monitoring of unstimulated 
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l NBT tests in hospitalized cystic fibrosis patients. Their suggestion was 
I 
l 
j 
l 
I 
that serial monitoring by means of the NBT test on such hospitalized 
patients would be useful in adding to the criteria used in determining 
improvement in condition. The results of the present study support this 
contention. It was hoped in this study that predictions could be made of 
impending exacerbations in pulmonary symptoms by serial results of the 
stimulated NBT test, according to the study of Curreri et al. (11). This 
was found not to be possible for some technical reasons to be discussed 
later. In the remaining figures (2a-f and 3a-f) including the moderate-
mild cystic fibrosis group (Fig. 2) and in the control group (Fig. 3), the 
only unusual event was the hospitalization of patient DH for acute ab-
dominal complaints at the end of the study. She was released asymptomatic 
after one week. From an inspection of Fig. la and c and 2a-f and 3a-f, it 
can be noted that the periodic variations as suggested by the study of Curreri 
et al. (11) is not evident in these results. Overall, the unstimulated ~BT 
test results in most of the cystic fibrosis patients (Fig. la, b, d; 2a, b, 
c, f) show either extremely variable results, or of those who don't, the 
results remain rather consistently high, i.e., values greater than 20% NBT 
positive PMNs. Certain control subjects also showed a variability in unstimu-
lated NBT test results, especially in Fig. 3d and e. This will be accounted 
for later in the discussion. Fig. 4 demonstrates the total unstimulated NBT 
test results from all cystic fibrosis patients and control subjects. There 
is a distinct difference between the three different groups. There seems, 
therefore, to exist a valid correlation not only between increased unstimu-
lated NBT test results with the events which occur in patients with cystic 
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I fibrosis, but that the test results increase also with the severity of these 
l events. These results, although somewhat higher overall, are consistent with the findings of Hill et al.(29) as well as those of Sullivan et al. (48). 
The average stimulated NBT test results are indicated in Fie. 5. A rela-
tively significant difference in the averages existed only between all 
cystic fibrosis patients and control subjects, but not between the two 
different cystic fibrosis patient zroups. It is also evident that from the 
high standard deviation indicated in Fig. 5 for the severely affected 
patients, that these results were more highly variable than in the other 
two groups. In comparison to the relatively smaller standard deviation of 
the moderate to mild cystic fibrosis patient group, the greater variability 
in the severely affected group may reflect the increased susceptibility 
of these patients to exacerbations of their pulmonary symptoms. As noted 
earlier, it was not possible to demonstrate the periodic variability in 
neutrophil function reflected in stimulated NBT test results. Also, there 
were more instances of unexpectedly high unstimulated NBT test results in 
control subjects. The most probable cause of these results rests with the 
test system and technique rather than with the subjects themselves. 
During the course of the project it was ascertained that simultaneously 
drawn samples of heparinized venous and capillary blood showed a distinct 
difference in stimulated NBT test results. In Fig. 6 the results are shown 
of two trials each of simultaneously drawn capillary and venous blood from 
a cystic fibrosis patient and a control subject. In both subjects the venous 
blood samples showed definitely higher stimulated NBT test values. These 
results are consistent with those obtained in similar experiments conducted 
64 
by Bjorksten (7). This indicates that venous blood samples probably 
represent a more accurate and truer index of maximum stimulation. A possible 
reason for this occurrence was the suggestion made by the above cited author 
(7) that certain interstitial tissue fluids obtained along with capillary 
drawn blood might, to a variable extent, inhibit neutrophilic NBT dye 
reduction. Another possibility became of concern. In the work of Benitez-
Bribiesca (6), it was discovered that NBT dye reduction became markedly 
reduced in the presence of levels of heparin greater than 100 I.U. per ml 
of blood. The maximum amounts of heparin in either capillary tube blood 
or Vacutainer blood were 75 I.U. heparin/ml blood and 30 I.U. heparin/ml 
blood, respectively. The averages for capillary and venous blood samples 
however were 50 I.U./ml and 30 I.U./ml respectively. Therefore, the 
possible effect of heparin on suppressing dye reduction in the NBT tests 
could be discounted in this case. The lability of the NBT test was further 
demonstrated from the results illustrated in Fig. 7. At the higher pre-
incubation temperature the unstimulated NBT test results increased after 
a period of time to render false high positive values. This may possibly 
be accounted for by an increased rate in some stimulatory degradation 
products in the blood samples. Another explanation is the possibility of 
an artifactual stimulation of the test by the presence of endotoxin in the 
blood collecting tubes. In fact from the positive results of the Limulus-
lysate endotoxin assay on the heparinized glass blood collecting tubes and 
pipettes this may well be the case. As observed earlier, there were a 
number of instances of unpredictedly high unstimulated NBT test results in 
afebrile, healthy control subjects, in spite of taking the precaution of 
innnersing the tubes in the ice water baths until assays were performed. 
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Although only very rough semiquantitative measurements can be made as to 
the actual amount of endotoxin present in each tube, by comparison with 
known standards, it seems that there was enough endotoxin present in each 
tube to produce a concentration of approximately 1 µgm/ml of (blood) 
sample within one order of magnitude in either direction. Endotoxin is 
often used, just as are latex particles, to produce an in vitro stimulation 
of phagocytosis. In the study of Matula and Paterson (36), endotoxin was 
added in varying amounts to the NBT test system to determine the threshhold 
of stimulation. Unfortunately the threshhold lies somewhere between the 
wide ranges of 0.5 µgm/ml (no stimulation) and 200 µgm/ml (high stimulation). 
In the stimulated NBT test system of Park (40), endotoxin is added to the 
blood dye solution mixture to a concentration of 10 µgm/ml. This means 
that in some of the tubes there is probably enough endotoxin present in 
certain of the blood collecting tubes to pass the 11 threshhold of stimu-
lation" and cause in vitro false high positive 11unstimulated 11NBT test. 
Although individual unstimulated NBT test results among healthy controls 
showed unpredicted high values in about 1 out of 6 total trials, the averages 
of all values for control subjects (13% NBT positive neutrophils) were 
similar to, although slightly higher than, those of other investigators 
using similar systems. Park et al. (41) found an average of 8.5% positive 
neutrophils from venous samples obtained from 30 healthy controls, while 
Fikrig and associates (20) using a method similar to that of Park et al.(41). 
found an average of 5% positive cells among 50 control subjects. The in-
accuracy of some NBT test results in this study has made the interpretation 
of some of the serial test studies difficult. However, the average value 
66 
of NBT test results, both stimulated (12.7%) and unstimulated (73.7%) for 
control subjects gives a baseline for comparison with the NBT values ob-
tained from cystic fibrosis patients. 
In order for the combined use of the stimulated and unstimulated NBT 
test to be more effective and accurate, steps must be taken to correct all 
of the above mentioned problems. In the future use of the NBT test for 
any reason, the absolute prerequisite is the establishment of a single, 
well controlled test system. 
From the results of the antibiotic sensitivity tests with all four 
antibiotics using the four strains tested, no significant differences 
exist between the antibiotic susceptibility of mucoid or non-mucoid 
organisms obtained from either of two patients studied: KN-mildly sympto-
matic (Shwachman score 82) and PZ-severely symptomatic (Shawchman score 
30). It would seem most probable from these results, that the mucoid slime 
layer does not contribute substantially to the pathogenicity of mucoid R_. 
aeruginosa merely by altering the organism's antibiotic sensitivity. This 
slime layer would seem, therefore, to be a loosely adherent, completely 
permeable substance incapable of contributing to the Pseudomonas cyto-
plasmic membrane's ability to exclude various antibiotics. The recent 
report by Anderson (3) further supports this contention. In this study 
he used gentamicin disc sensitivity tests on mucoid and non-mucoid iso-
lates of!'.._. aeruginosa from cystic fibrosis patients. His results on 
strains obtained both from throat and sputum cultures showed similar 
antibiograms of mucoid and non-mucoid isolates from their respective 
source. 
SUMMARY 
Twenty eight patients with cystic fibrosis were involved in studies 
of respiratory tract infection by Pseudomonas aeruginosa. The nitroblue 
tetrazolium (NBT) tests on neutrophil function, and the antibiotic sensi-
tivity of mucoid isolates and their respective non-mucoid revertants of 
f · aeruginosa strains obtained from selected patients were also deter-
mined. In the study of the respiratory tract infections it was determined 
that P. aeruginosa pyocine types UT, 3E, and lB predominated as infecting 
organisms, and that patients with more severe overall symptoms tended to 
be infected more often b1 mucoid than by non-mucoid strains. NBT test 
results showed a significant correlation between the events occurring in 
patients with cystic fibrosis and above normal unstimulated NBT test 
results. The results of the serial stimulated NBT tests were not able to 
predict exacerbations of pulmonary symptoms. The antibiotic sensitivity 
tests revealed no significant differences in antibiograms of mucoid isolates 
and their respective non-mucoid revertants using carbenicillin, gentamicin, 
tobramycin and sodium colistimethate. 
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